

業 績 目 録（令和元年）

教室・部門名 分子診断・治療医学

(A-a) 英文著書

(A-b) 和文著書

(B-a) 英文総説

(B-b) 和文総説

(C-a) 英文原著

1. Matsumoto Y, Chinen Y, Shimura Y, Nagoshi H, Sasaki N, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Uchiyama H, Taki T, Horiike S, Kuroda J, Taniwaki M. Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma. [published online ahead of print, 2019 Nov 4]. **Int J Hematol.** 2019;10.1007/s12185-019-02766-z. doi:10.1007/s12185-019-02766-z. (IF= 2.350)
2. Hosokawa K, Mizumaki H, Elbadry MI, Saito C, Espinoza JL, Thi Thanh Dao A, Katagiri T, Harashima A, Kikuchi A, Kanai A, Matsui H, Inaba T, Taniwaki M, Yamamoto Y, Nakao S. Clonal hematopoiesis by SLIT1-mutated hematopoietic stem cells due to a breakdown of the autocrine loop involving Slit1 in acquired aplastic anemia. **Leukemia.** 2019 Nov;33(11):2732-2766. doi: 10.1038/s41375-019-0510-0. (IF= 8.665)
3. Yoshida M, Matsumoto Y, Suzuki T, Nishimura S, Kato T, Shimura K, Kaneko H, Taniwaki M. Corrosive injury of upper gastrointestinal tract by calcium oxide. **Indian J Gastroenterol.** 2019 Oct;38(5):460-461. doi: 10.1007/s12664-019-00992-1. PMID: 31691899. (IF= 1.080)
4. Iida S, Watanabe T, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K,

Izutsu K, Ishikawa T, Shumiya Y, Tobinai K. Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. **Cancer Sci.** 2019 Sep;110(9):2924-2932. doi: 10.1111/cas.14139. Epub 2019 Aug 10. PMID: 31336012; PMCID: PMC6726678. (IF= 4.966)

5. Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. **Ann Hematol.** 2019 Jan;98(1):131-142. doi: 10.1007/s00277-018-3418-2. (IF= 2.840)

6. Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. EWSR1 overexpression is a pro-oncogenic event in multiple myeloma. **Int J Hematol.** 2020 Oct 23. doi: 10.1007/s12185-020-03027-0. (血液内科学との共同研究) (IF= 2.350)

7. Isa R, Uoshima N, Takahashi R, Nakano-Akamatsu S, Kawata E, Kaneko H, Shimura K, Kamitsuji Y, Takimoto-Shimomura T, Mizutani S, Chinen Y, Ohshiro M, Fujino T, Kawaji Y, Uchiyama H, Sasaki N, Tsukamoto T, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. **Ann Hematol.** 2020 Jan;99(1):137-145. doi: 10.1007/s00277-019-03859-9. (血液内科学との共同研究) (IF= 2.840)

8. Matsumoto Y, Kobayashi T, Shimura Y, Kawata E, Nagoshi H, Ohshiro M, Sugitani M, Shimura K, Iwai T, Fuchida SI, Yoshida M, Kiyota M, Mizutani S, Chinen Y, Takimoto-Shimomura T, Nakao M, Kaneko H, Uchiyama H, Uoshima N, Nishigaki H, Kobayashi Y, Horiike S, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study

Group (KOTOSG). Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. **Int J Hematol.** 2019 Jul;110(1):77-85. doi: 10.1007/s12185-019-02650-w. 血液内科学との共同研究) (IF= 2.350)

9. Mizuno Y, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Matsumura-Kimoto Y, Fujibayashi Y, Kuwahara-Ota S, Fujino T, Nishiyama D, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma. **Int J Hematol.** 2019 May;109(5):593-602. doi: 10.1007/s12185-019-02617-x. (血液内科学との共同研究) (IF= 2.350)
10. Sasaki N, Shimura K, Yoshida M, Uoshima N, Kiyota M, Hatsuse M, Uchiyama H, Chinen Y, Kobayashi T, Nakao M, Takahashi R, Nakano-Akamatsu S, Kaneko H, Kobayashi Y, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) investigators. Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients. **Int J Hematol.** 2019 Mar;109(3):278-285. doi: 10.1007/s12185-018-02583-w. (IF= 2.350)
11. Takimoto-Shimomura T, Tsukamoto T, Maegawa S, Fujibayashi Y, Matsumura-Kimoto Y, Mizuno Y, Chinen Y, Shimura Y, Mizutani S, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. **Invest New Drugs.** 2019 Apr;37(2):210-222. doi: 10.1007/s10637-018-0623-8. (血液内科学との共同研究) (IF= 2.61)

(C-b) 和文原著

(D) 学会発表 (国内学会での一般演題は記載しない)

I) 特別講演、教育講演等

II) シンポジウム、ワークショップ、パネルディスカッション等

III) 国際学会における一般発表

1. Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K, Nagai H. Long-term follow-up of JCOG0406 study: Intensive immunochemotherapy (R-HIGH CHOP/CASER) followed by high-dose chemotherapy (LEED) with auto-PBSCT in untreated mantle cell lymphoma. 24th Congress of European Hematology Association (EHA24). June 15, 2019. Amsterdam, Netherland.

2. Kuwahara-ota S, Shimura Y, Isa R, Yamaguchi J, Fujibayashi Y, Nishiyama D, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Myeloma-induced myeloid-derived suppressor cells are targeted by immunomodulatory drugs that regulate the CCL5/CCR5 axis and mif and IRF8 expression. 24th Congers of European hematology Association. June 15,2019. Amsterdam, Netherland. (血液内科学との共同研究)

(E) 研究助成（競争的研究助成金）

総額 184 万円

公的助成

代表（総額）・小計 100 万円

- 1 文部科学省科学研究費助成事業 基盤研究 (C) 平成 30～32 年度
ファミリー遺伝子に内在する新たな造血白血病活性抑制機構の解明
助成金額 100 万円

財団等からの助成

代表（総額）・小計 84 万円

- 1 一般社団法人日本血液学会 研究助成 令和元 (2019) 年度
難治性血液腫瘍における長鎖非コード RNA PVT1, 遺伝子内エクソン再配列,

連結遺伝子の解析と臨床応用 助成金額 50 万円

2 群馬大学生体調節研究所共同研究拠点助成 令和元（2019）年度

ARG チロシンキナーゼによる白血病発症機構の解明 助成金額 34 万円